NVCT

19.3902.27%
ML

Matthew Lee Kaplan

Independent Director

Mr. Matthew Lee Kaplan, also known as Matt, served as a Managing Director and Head of Healthcare Equity Research at Ladenburg Thalmann & Co. Inc., Research Division. Mr. Kaplan was employed at the firm till January 2024. He covered biotechnology sector with a focus on therapeutic companies, cardiovascular, and drug delivery within the healthcare and life sciences equity research at the firm. Prior to this, he was a Partner and the Director of Healthcare Research at Punk, Ziegel & Company. Previously, Mr. Kaplan was a Senior Biotechnology Analyst at Evolution Capital and a Director of The Life Sciences Group at The Carson Group. Before that, he had experience as a Research Associate at the Albert Einstein College of Medicine and Montefiore Hospital Department of Cardiology. Mr. Kaplan has experience as a Biotechnology Analyst. He is a Co-Author of numerous articles on gene regulation in the heart. He is a Director of Nuvectis Pharma Inc. since September 2021. Mr. Kaplan received a B.S. in Biology from University of Michigan and studied Cellular and Molecular Biology at Columbia University.

Positions